Pictet Asset Management SA increased its holdings in shares of Evolent Health, Inc. (NYSE:EVH – Free Report) by 7.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,810 shares of the technology company’s stock after purchasing an additional 717 shares during the quarter. Pictet Asset Management SA’s holdings in Evolent Health were worth $351,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the business. Point72 Asset Management L.P. lifted its stake in Evolent Health by 83.5% in the fourth quarter. Point72 Asset Management L.P. now owns 3,270,676 shares of the technology company’s stock valued at $91,841,000 after acquiring an additional 1,487,856 shares during the last quarter. Norges Bank acquired a new stake in Evolent Health in the fourth quarter valued at $23,743,000. Vanguard Group Inc. lifted its stake in Evolent Health by 10.1% in the third quarter. Vanguard Group Inc. now owns 8,655,790 shares of the technology company’s stock valued at $311,004,000 after acquiring an additional 793,082 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Evolent Health by 1,894.5% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 753,086 shares of the technology company’s stock worth $27,060,000 after buying an additional 715,327 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its stake in shares of Evolent Health by 145.9% during the 2nd quarter. Macquarie Group Ltd. now owns 1,184,568 shares of the technology company’s stock worth $36,378,000 after buying an additional 702,899 shares during the last quarter.
Evolent Health Price Performance
NYSE:EVH opened at $25.72 on Wednesday. Evolent Health, Inc. has a 52 week low of $21.83 and a 52 week high of $39.78. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of -36.74 and a beta of 1.53. The firm’s 50-day simple moving average is $28.78 and its 200 day simple moving average is $31.25. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.07.
Insider Buying and Selling at Evolent Health
In related news, President Daniel Joseph Mccarthy sold 1,000 shares of Evolent Health stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $31.44, for a total transaction of $31,440.00. Following the sale, the president now directly owns 206,333 shares of the company’s stock, valued at approximately $6,487,109.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Frank J. Williams sold 110,000 shares of Evolent Health stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $29.52, for a total transaction of $3,247,200.00. Following the sale, the director now directly owns 819,812 shares in the company, valued at approximately $24,200,850.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, President Daniel Joseph Mccarthy sold 1,000 shares of Evolent Health stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $31.44, for a total transaction of $31,440.00. Following the sale, the president now owns 206,333 shares in the company, valued at $6,487,109.52. The disclosure for this sale can be found here. Insiders have sold a total of 160,474 shares of company stock valued at $4,804,088 in the last ninety days. 3.30% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
EVH has been the subject of a number of research reports. Guggenheim restated a “buy” rating and set a $47.00 target price on shares of Evolent Health in a research note on Monday, August 14th. StockNews.com initiated coverage on shares of Evolent Health in a research note on Thursday, May 18th. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.56.
Evolent Health Profile
Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.
- Five stocks we like better than Evolent Health
- Manufacturing Stocks Investing
- 3 Inexpensive Mid Cap Tech Stocks With Good Growth Prospects
- 5 Top Rated Dividend Stocks to Consider
- 3 Reasons the Dick’s Sporting Goods Selloff Is a Steal
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- Foot Locker Stock Takes a Big Hit…Is It a Retail Bargain?
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.